IDEXX Laboratories, Inc. (NASDAQ:IDXX) Position Raised by DAVENPORT & Co LLC

DAVENPORT & Co LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 20.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,793 shares of the company's stock after purchasing an additional 1,140 shares during the quarter. DAVENPORT & Co LLC's holdings in IDEXX Laboratories were worth $2,853,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Golden State Wealth Management LLC boosted its position in IDEXX Laboratories by 3,766.7% during the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company's stock worth $49,000 after purchasing an additional 113 shares during the period. Sagespring Wealth Partners LLC purchased a new stake in shares of IDEXX Laboratories in the first quarter worth about $229,000. Banque Transatlantique SA purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $2,681,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of IDEXX Laboratories by 13.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 25,553 shares of the company's stock valued at $10,731,000 after buying an additional 2,931 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of IDEXX Laboratories by 9.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,436 shares of the company's stock valued at $1,007,000 after buying an additional 218 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IDXX. Jefferies Financial Group started coverage on IDEXX Laboratories in a report on Tuesday. They issued a "buy" rating and a $625.00 price target for the company. Leerink Partners upped their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Stifel Nicolaus upped their price objective on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research report on Wednesday. Finally, Morgan Stanley raised their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $558.11.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director directly owned 1,801 shares of the company's stock, valued at approximately $922,724.34. The trade was a 41.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Up 0.7%

Shares of IDEXX Laboratories stock traded up $3.60 during trading on Friday, reaching $546.31. The company had a trading volume of 339,027 shares, compared to its average volume of 645,880. The company has a market cap of $43.93 billion, a price-to-earnings ratio of 50.49, a price-to-earnings-growth ratio of 3.99 and a beta of 1.54. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $548.54. The firm's fifty day moving average is $510.63 and its 200-day moving average is $454.55. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. During the same quarter last year, the business posted $2.71 EPS. IDEXX Laboratories's quarterly revenue was up 3.6% compared to the same quarter last year. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.